

Brief Research Report

Compliance with Highly Active Antiretroviral Therapy (HAART) does not Prevent Human Papilloma Virus (HPV)-Related Cancers in Women Infected with Human Immunodeficiency Virus (HIV)

Katherine Rogg, MD¹; William R. Robinson, MD^{2*}

¹Department of Gynecology and Obstetrics, University of Rochester, School of Medicine, Rochester, New York, USA

²Department of Gynecology and Obstetrics, Tulane University, School of Medicine, New Orleans, Louisiana, USA

*Corresponding author

William R. Robinson, MD

Professor, Department of Gynecology and Obstetrics, Tulane University School of Medicine, 1430 Tulane Ave. SL-11, New Orleans, Louisiana 70112, USA; Tel. 504-988-6121; Fax. 504-988-1846; E-mail: wrobinso@tulane.edu

Article information

Received: April 18th, 2019; Revised: June 12th, 2019; Accepted: June 13th, 2019; Published: June 24th, 2019

Cite this article

Rogg K, Robinson WR. Compliance with highly active antiretroviral therapy (HAART) does not prevent human papilloma virus (HPV)-related cancers in women infected with human immunodeficiency virus. *Gynecol Obstet Res Open J*. 2019; 6(1): 6-10. doi: [10.17140/GOROJ-6-149](https://doi.org/10.17140/GOROJ-6-149)

ABSTRACT

Introduction

Cancer is one of the leading causes of death in people with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), due to behavioral choices and overlapping risk factors.

Aim

The purpose of this report is to determine the long-term incidence of human papilloma virus (HPV)-associated cancer in women with pre-invasive cervical neoplasia, and compliance with medication and cancer screening recommendations.

Methods

HIV-infected women diagnosed with pre-invasive cervical neoplasia and an HPV-associated malignancy between 1995-2008 were identified. Data collected includes: demographics, HIV treatment/response, malignancy treatment/response, other healthcare utilization, use of health navigators, and compliance.

Results

Seventy one subjects were identified with HIV infection, cervical dysplasia, and at least ten years' follow-up. 17/71 (24%) were identified with an HPV-related malignancy. The mean age of those diagnosed with HPV-related malignancy was 39-years. Malignancies included: Cervix-9, Vulva-7, Anal-4, Vagina-3, Urethra/Bladder-2, Oropharyngeal-3. Eight also had *in-situ* neoplasms: Cervix-4, Vulva-3, Oropharyngeal-1. Four subjects had 3 separate malignancies, and two others had 2 malignancies. Compliance with HAART correlated strongly with immunocompetence, response to therapy, use of patient navigators, and survival. Sixty out of seventy one (84.5%) subjects underwent screening mammography, 57/71 (80.3%) underwent colonoscopy, and 67/71 (94.3%) underwent pap smear testing. Compliance with screening compared favorably with the general population, and overall survival was similar.

Discussion and Conclusion

The long-term incidence and mortality from cancer in women with HIV and cervical dysplasia appears to be comparable to that seen in the general population, with the possible exception of oropharyngeal cancers. Compliance with cancer screening recommendations appears to be higher than in the general population. This suggests that structured primary care programs for HIV-infected women are effective in prevention/early diagnosis of cancer. Standardized screening programs for oropharyngeal cancers should be considered in this population.

Keywords

Human immunodeficiency virus (HIV); Cancer; Human papilloma virus(HPV); Women; AIDS; Highly active anti-retroviral therapy (HAART).

INTRODUCTION

Cancer is one of the leading causes of death in people with human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS).^{1,2} With the introduction of highly active anti-retroviral therapy (HAART) in the mid-1990s, the overall incidence and mortality of cancer has decreased in this population, largely due to striking declines in AIDS-defining cancers such as Kaposi sarcoma and non-Hodgkin lymphoma.³ However, the incidence of invasive cervical carcinoma, (also an AIDS-defining cancer) has been relatively stable; while a number of non-AIDS defining cancers have increased in incidence (presumably due to the increasing numbers and age of HIV-infected individuals) and now constitute the majority of cancers in this population.^{4,5} Factors suspected to contribute to increased cancer incidence in HIV-infected persons include HIV viremia, immune deficiency, oncogenic virus co-infection, and lifestyle exposures (e.g. tobacco, alcohol).^{6,7,8} In particular, among individuals with AIDS, a statistically significant elevated risk of human papilloma virus (HPV)-associated cancers has been reported, with the level of risk strongly correlated with increased levels of immune suppression.⁹

Although HIV-associated malignancies have been extensively analyzed and reported, the data on cancers in women, with the exception of invasive cervical cancer, has been relatively limited due to an overall paucity of women in study populations.¹⁰ Further, many of these studies involved populations with multiple additional risk factors for cancer in addition to HIV infection, such as intravenous drug users or men who have sex with men.¹¹ In contrast to earlier reports, which typically included relatively few HIV-infected women, as well as a relatively short follow-up, the

goal of this study is to determine the incidence and outcomes of HPV-related genital and non-genital tract malignancies in HIV-infected women with a diagnosis of pre-invasive cervical neoplasia (dysplasia) and at least a 10-year follow-up. Further, as screening programs have been shown to be very effective in reducing the incidence of invasive cervical cancer in HIV-infected women,¹² the secondary goal of this study is to evaluate the degree of compliance with cancer screening recommendations in this cohort.

METHODS

As part of a facility-based quality improvement (QI) program, all HIV-infected women diagnosed with an HPV-associated malignancy between 1995-2008 were identified. Data sources included standard medical records, tumor registries, and clinical research trial records. Data collected includes: demographics, HIV treatment/response, malignancy treatment/response, other healthcare utilization, use of health navigators, and compliance. The data was analyzed using standard statistical tests, and the study was determined to be exempt from Institutional Review Board (IRB) review.

RESULTS

Seventy one subjects were identified with HIV infection, cervical dysplasia, and at least ten years' follow-up data from a large, inner-city academic institution in New Orleans, Louisiana, USA. Seventeen out of seventy one (24%) were identified with an human papilloma virus (HPV)-related malignancy. The mean age of those diagnosed with HPV-related malignancy was 39-years and all were African-American. Invasive malignancies included: Cervix-9, Vulva-7, Anal-4, Vagina-3, Urethra/Bladder-2, Oropharyngeal-3. Eight

Table 1. Characteristics of HIV-Infected Women with Cervical Dysplasia and at Least one HPV-Associated Malignancy

Subjects	Age	Cervix	Vulva	Anal	Vagina	Urethra/bladder	Oropharyngeal	Cervix IS	Vulva IS	Oro IS	HAART Compliance	CD4>200	Patient navigator	Survival
1	45	x	x				x							27
2	52		x					x			x	x	x	N/A
3	50	x		x			x		x					19
4	34	x	x							x	x	x	x	N/A
5	30			x				x			x	x	x	N/A
6	35	x				x								21
7	37				x			x			x	x	x	N/A
8	51	x	x		x									9
9	29				x						x	x	x	N/A
10	45		x								x	x	x	N/A
11	38	x					x		x		x			13
12	33	x									x	x	x	N/A
13	60			x				x			x	x	x	N/A
14	32	x	x			x					x	x	x	N/A
15	30										x	x	x	N/A
16	36	x		x					x		x	x	x	28
17	28		x											18

IS=In-Situ; Survival in months; N/A=living at time of this analysis

additional subjects had *in-situ* neoplasms which included: Cervix-4, Vulva-3, Oropharyngeal-1. Four subjects had 3 separate malignancies, and two others had 2 malignancies correlated strongly with survival. Compliance with HAART correlated strongly with immunocompetence, (as measured by CD4>200/ μ L) response to anti-malignancy therapy, and survival. Further, compliance correlated strongly with the use of patient advocate/navigators (Table 1).

Thirty five out of seventy one (49%) participated in federally-sponsored clinical trials, including AIDS Clinical Trial Group (ACTG) 200, ACTG 293, Southwest Oncology Group (SWOG) 8797, Gynecologic Oncology Group (GOG) 154, and GOG 155. Sixty out of seventy one (84.5%) subjects underwent screening mammography, 57/71 (80.3%) underwent colonoscopy, and 67/71 (94.3%) underwent pap smear testing, all in accordance with American Cancer Society (ACS) guidelines. The level of compliance with guideline-based screening compared very favorably with that seen in the general population of New Orleans and Louisiana, USA, and overall survival at 5-years was similar.¹³

DISCUSSION

In this cohort, the long-term incidence and mortality from HPV-associated cancers in HIV-infected women with a history of cervical dysplasia was comparable to that seen in women with cervical dysplasia in the general population of this area. This appears to be in contrast with previous reports, which found an increased risk of both AIDS-defining and non-AIDS defining cancers in similar populations.¹⁴ It seems clear from these findings that while the use of HAART can reduce the risk of HPV-associated cancers in this group to at least that of the general population, it does not prevent those cancers, and therefore active screening remains important, even in those HIV-infected individuals who remain compliant with their medications. A possible explanation for these findings include strong compliance with HAART as seen here, which is known to be protective for both AIDS-defining and non-AIDS defining cancers. Another explanation could be the increased level of compliance with cancer screening recommendations in this group. While HIV-infected patients with cervical dysplasia are at risk for HPV-associated cancers, that risk does not seem to exceed that seen in the general population of this area, which has long been among the highest in the US.¹⁵ This apparent success in cancer screening is likely due to the work of a well-organized and (relatively) well-funded clinic system for HIV-infected individuals in the New Orleans Metropolitan area. This system has been in existence for over 25-years, makes extensive use of patient advocate/navigators, and has been credited with dramatic improvements in multiple health outcomes.¹⁶ This suggests that communities where HIV infection is common will benefit from organized primary care delivery systems, with emphasis on adherence to HAART.

Another possible explanation for the findings reported here is that the baseline characteristics of this group differ from those in prior studies. This study population, while limited in size, was exclusively female and appeared to have both similar levels of personal risk factors and similar demographics to the general population of the area. Prior studies of cancer risks in HIV-infected persons typically comprised a cohort that was predominantly

male and included many additional known risk factors for cancer, including high rates of intravenous drug use, alcohol use, smoking, and infection with known cancer-causing viruses such as Hepatitis B and C viruses, (HBV and HCV) in addition to HPV.¹⁷

It is well-known that HIV-infected women from the pre-HAART era demonstrated an elevated risk for and mortality from cervical abnormalities and dysplasia.¹⁸ A study by Ellerbrock et al, reported that 1 in 5 HIV-infected women without previous evidence of cervical dysplasia developed biopsy-confirmed cervical squamous intraepithelial lesions.¹⁹ In addition, HIV-infected women with a greater level of immune suppression have an increased risk of persistent HPV infection and progression to cervical dysplasia.²⁰ Interestingly, a separate study showed that the incidence of cervical dysplasia in HPV-negative, cytology-negative HIV-infected women with CD4 counts greater than 500/ μ L was comparable to that in HIV-negative women.²¹ Massad et al found that while the risk for an abnormal Pap test was greater in HIV-infected women than seronegative women, once an HIV-infected woman develops an abnormality, her risk for high grade cervical dysplasia was only marginally greater than that of seronegative women.²² Of importance for patient care, another study of HIV seropositive women from 1994-2001 from the same investigators found the risk of invasive cervical cancer to be indistinguishable from that of the general population when the HIV seropositive women were enrolled in a program of cervical cancer screening and prevention.^{23,24}

An intriguing finding from the current study is that the long-term incidence of oropharyngeal cancers may be higher than expected. This may be partially explained as a reflection of the overall increase in oral HPV infection and oropharyngeal cancers in recent years.²⁵ However, understanding of the pathophysiology of HPV is incomplete, and may differ in the female genital tract compared to the oropharyngeal tract. Consistent with this, a study by Beachler, et al, found an elevated prevalence of oral HPV in HIV-infected persons after controlling for differences in cigarette smoking and sexual behavior.²⁶ This unexpected number of oropharyngeal cancers in HIV-infected persons suggests that standardized screening programs for oropharyngeal cancers should be considered.

Compliance with cancer screening recommendations in this study group appeared to be higher than in the general population. Although there is limited data on certain cancers in HIV-infected women, prior studies have indicated benefits of screening these patients for cervical cancer, anal cancer, breast cancer, and hepatocellular carcinoma.²⁷ Currently there is insufficient evidence to recommend lung cancer screening for HIV-infected women without other risk factors such as smoking. Although the incidence of lung cancer is elevated in HIV patients, it has also been reported that they have a greater cumulative pack-year smoking history.²⁸

CONCLUSION

The long-term incidence and mortality from cancer in women with HIV and cervical dysplasia appears to be comparable to that seen in the general population, with the possible exception of oropha-

ryngeal cancers. Compliance with cancer screening recommendations appears to be higher than in the general population. This suggests that structured primary care programs for HIV-infected women are effective in prevention/early diagnosis of cancer. Standardized screening programs for oropharyngeal cancers should be considered in this population.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

- Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): Trends since 2000. *AIDS*. 2014; 28: 1181-1191. doi: [10.1097/QAD.0000000000000222](https://doi.org/10.1097/QAD.0000000000000222)
- Trickey A, May MT, Vehreschild J, et al. Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy. *PLoS One*. 2016; 11(8): e0160460. doi: [10.1371/journal.pone.0160460](https://doi.org/10.1371/journal.pone.0160460)
- Park LS, Tate JP, Sigel K, et al. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012. *AIDS*. 2016; 30(11): 1795-1806. doi: [10.1097/QAD.0000000000001112](https://doi.org/10.1097/QAD.0000000000001112)
- Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among people with AIDS in the United States. *Cancer*. 2011; 117(5): 1089-1096. doi: [10.1002/cncr.25547](https://doi.org/10.1002/cncr.25547)
- Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. *J Natl Cancer Inst*. 2011; 103(9): 753-762. doi: [10.1093/jnci/djr076](https://doi.org/10.1093/jnci/djr076)
- Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, Immunodeficiency, Viral replication and the risk of cancer. *Cancer Epidemiol Biomarkers Prev*. 2011; 20(12): 2551-2559. doi: [10.1158/1055-9965.EPI-11-0777](https://doi.org/10.1158/1055-9965.EPI-11-0777)
- Riedel DJ, Rositch AF, Redfield RR. Patterns of HIV viremia and viral suppression before diagnosis of non-AIDS-defining cancers in HIV-infected individuals. *Infect Agent Cancer*. 2015; 10: 38. doi: [10.1186/s13027-015-0033-x](https://doi.org/10.1186/s13027-015-0033-x)
- Park LS, Hernandez-Ramirez RU, Silverberg MJ, Crothers K, Dubrow R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: A meta-analysis. *AIDS*. 2016; 30(2): 273-291. doi: [10.1097/QAD.0000000000000922](https://doi.org/10.1097/QAD.0000000000000922)
- Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. *Int J Cancer*. 2008; 123: 187-194. doi: [10.1002/ijc.23487](https://doi.org/10.1002/ijc.23487)
- Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. *J Natl Cancer Inst*. 2009; 101(16): 1120-1130. doi: [10.1093/jnci/djp205](https://doi.org/10.1093/jnci/djp205)
- Marcus JL, Chao C, Leyden WA, et al. Survival Among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. *Cancer Epidemiol Biomarkers Prev*. 2015; 24(8): 1167-1173. doi: [10.1158/1055-9965.EPI-14-1079](https://doi.org/10.1158/1055-9965.EPI-14-1079)
- Abraham AG, Strickler HD, Jing Y, et al. Invasive cervical cancer risk among HIV-infected women: A North American multi-cohort collaboration prospective study. *J Acquir Immune Defic Syndr*. 2013; 62(4): 405-413. doi: [10.1097/QAI.0b013e31828177d7](https://doi.org/10.1097/QAI.0b013e31828177d7)
- Louisiana Breast and Cervical Cancer Health Program. Web site. <http://lbchp.org/breast-cancer/>. 2017. Accessed April 17, 2019.
- Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: A 20-year cohort study. *AIDS*. 2009; 23(1): 41-50. doi: [10.1097/QAD.0b013e328317cc2d](https://doi.org/10.1097/QAD.0b013e328317cc2d)
- Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. *AIDS*. 2009; 23(17): 2337-2345. doi: [10.1097/QAD.0b013e3283319184](https://doi.org/10.1097/QAD.0b013e3283319184)
- Clark RA, Mirabelli R, Shafe J, Broyles S, Besch L, Kissinger P. The new orleans HIV outpatient program patient experience with hurricane katrina. *J La State Med Soc*. 2007; 159(5): 276, 278-279, 281.
- Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS in the United States. *Arch Intern Med*. 2010; 170(15): 1337-1345. doi: [10.1001/archinternmed.2010.253](https://doi.org/10.1001/archinternmed.2010.253)
- Adler DH, Wallace M, Bennie T, et al. Cumulative impact of HIV and multiple concurrent human papillomavirus infections on the risk of cervical dysplasia. *Adv Virol*. 2016; 2016: 7310894. doi: [10.1155/2016/7310894](https://doi.org/10.1155/2016/7310894)
- Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. *JAMA*. 2000; 283(8): 1031-1037. doi: [10.1001/jama.283.8.1031](https://doi.org/10.1001/jama.283.8.1031)
- Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. *J Natl Cancer Inst*. 2005; 97: 577-586. doi: [10.1093/jnci/dji073](https://doi.org/10.1093/jnci/dji073)
- Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. *JAMA*. 2005; 293(12): 1471-1476. doi: [10.1001/jama.293.12.1471](https://doi.org/10.1001/jama.293.12.1471)
- Massad LS, Pierce CB, Minkoff H, et al. Long-term cumulative incidence of cervical intraepithelial neoplasia grade 3 or worse after abnormal cytology: Impact of HIV infection. *Int J Cancer*. 2014; 134(8): 1854-1861. doi: [10.1002/ijc.28523](https://doi.org/10.1002/ijc.28523)

23. Massad LS, Seaberg EC, Watts DH, et al. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. *AIDS*. 2004; 18: 109-113.
24. Robinson W, Freeman D. Improved outcome of cervical neoplasia in HIV-infected women in the highly active antiretroviral therapy (HAART) era. *AIDS Patient Care STDS*. 2002; 16(2): 61-65.
25. Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. *Oral Oncol*. 2014; 50(5): 380-386. doi: [10.1016/j.oraloncology.2013.12.019](https://doi.org/10.1016/j.oraloncology.2013.12.019)
26. Beachler DC, Weber KM, Margolick JB, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. *Cancer Epidemiol Biomarkers Prev*. 2012; 21(1): 122-133. doi: [10.1158/1055-9965.EPI-11-0734](https://doi.org/10.1158/1055-9965.EPI-11-0734)
27. Sigel K, Dubrow R, Silverberg M, Crothers K, Braithwaite S, Justice A. Cancer screening in patients infected with HIV. *Curr HIV/AIDS Rep*. 2011; 8(3): 142-152. doi: [10.1007/s11904-011-0085-5](https://doi.org/10.1007/s11904-011-0085-5)
28. Tyerman Z, Aboulafla DM. Review of screening guidelines for non-AIDS-defining malignancies: Evoking issues in the era of highly active antiretroviral therapy. *AIDS Rev*. 2012; 14(1): 3-16.